Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186838 | 0.94 | CYP4F2 (0.68) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL186284 | 0.92 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL9871166 | 0.92 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL2142612 | 0.92 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL186818 | 0.92 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL7159911 | 0.91 | CYP4F2 (0.56) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17756702 | 0.88 | CYP4F2 (0.60) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL1398455 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17762731 | 0.86 | CYP4F2 (0.58) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL9482334 | 0.86 | CYP4F2 (0.47) | CYP4F2CYP4A11PPARAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703422-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISEASE, DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; DISORDER OF GLUCOSE METABOLISM; ALZHEIMER'S DISEASE; SYNDROME X; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ASSOCIATED DISORDER | ESPERION THERAPEUTICS, INC. | 2004-03-09 | — | — | US | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3860999-B1 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-0320501-A2 | Phenoxy derivatives, their preparation, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-06-14 | — | — | EP | disclosed |
| US-4798838-A | ANTICOAGULANTS, ANTICHOLESTEROL AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-01-17 | — | — | US | disclosed |
| US-4795753-A | Certain pyridyl or imidazol-1-yl-alkyleneoxy-(or amino)phenoxy-alkanoates having lipid lowering activity | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| US-4794113-A | ANTICHOLESTEROL, ANTILIPEMIC, ANTICOAGULANT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-12-27 | — | — | US | disclosed |
| EP-0130077-A2 | Phenoxy derivatives, their preparation, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4410537-A | 3-HYDROXY-2-FORMYLPHENOXYPENTANOIC ACID DERIVATIVES | BURROUGHTS WELLCOME CO. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4374845-A | INHIJBIT DIOSYNTHESIS OF THROMBOXANE A2, ANTIINFLAMMATORY, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | KISSEI PHARMACEUTICAL CO. (JP) | 1983-02-22 | — | — | US | disclosed |
| EP-0022229-B1 | SUBSTITUTED PHENOL ETHERS, THEIR PREPARATION, INTERMEDIATES THEREFOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE PREPARATION THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-12-08 | — | — | EP | disclosed |
| EP-0022229-A1 | Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | CYP4F2 981/4885CYP4A11 132/4885PKM 388/4885 |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CYP4F2 847/4885CYP4A11 552/4885PKM 1257/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | CYP4F2 690/4885CYP4A11 346/4885PKM 1586/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | CYP4F2 847/4885CYP4A11 552/4885PKM 1257/4885 |
| US-20240415847-A1 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | GAA, LCT, MGAM | CYP4F2 1368/4885CYP4A11 1421/4885PKM 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.